Christoph Ahlgrim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christoph Ahlgrim has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Torben Pottgiesser
Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine University of Freiburg Freiburg im Breisgau Germany
11 shared publicationsPhilipp Birkner
Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine University of Freiburg Freiburg im Breisgau Germany
6 shared publicationsFlorian Seiler
Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine University of Freiburg Freiburg im Breisgau Germany
5 shared publications- Kai Roecker
Hochschule Furtwangen
5 shared publications Sebastian Grundmann
Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine University of Freiburg Freiburg im Breisgau Germany
5 shared publicationsSebastian Ruthardt
5 shared publications
Latest Publications
- 27 January 2026
- Published by Springer Nature in Die Innere Medizin
- Vol. 67 (3) , 363-365
Revival von Digitoxin als Therapieoption bei fortgeschrittener Herzinsuffizienz?
- 27 January 2026
- Published by Springer Nature in Die Innere Medizin
- Vol. 67 (3) , 363-365
Revival von Digitoxin als Therapieoption bei fortgeschrittener Herzinsuffizienz?
- Open Access
- 6 October 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5901
Pulmonary Capillary Wedge Pressure during Exercise Is Prognostic for Long-Term Survival in Patients with Symptomatic Heart Failure
Aims: Exercise stress testing can stratify specific populations of heart failure patients for mortality risk, but is not universally applied. The aim of the present study was to investigate the prognostic capabilities of invasive exercise testing in a real-world cohort of suspected heart failure patients in whom non-cardiac causes of dyspnea were excluded. Methods: We retrospectively analyzed the survival of 682 patients who underwent right heart catheterization at rest and during exercise between 2007 and 2017 for dyspnea and expected heart failure. Pulmonary capillary wedge pressure (PCWP) at rest and the PCWP response to exercise, expressed as the ratio of PCWP at peak exercise to workload normalized to body weight (PCWL (mmHg/W/kg)), were determined. Mortality data were retrieved from the official German death registry. Results: Over a median follow-up period of 8.5 years, PCWL is a stronger predictor of all-cause mortality than PCWP. Patients featuring a reduced left ventricular ejection fraction (LVEF; p = 0.719). Irrespective of LVEF, an increased PCWL during exercise was associated with a significantly increased mortality (HR 1.950 with preserved LVEF, 95% CI 1.12–3.34, p = 0.018; and HR 3.212 with impaired LVEF, 95% CI 1.75–5.70, p < 0.001). Conclusions: In patients with clinical heart failure, invasive exercise testing improves the prediction of mortality. Subjects with a favorable response to exercise have a relatively low mortality irrespective of left ventricular systolic function.
- 6 October 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5901
Open AccessPulmonary Capillary Wedge Pressure during Exercise Is Prognostic for Long-Term Survival in Patients with Symptomatic Heart Failure
Aims: Exercise stress testing can stratify specific populations of heart failure patients for mortality risk, but is not universally applied. The aim of the present study was to investigate the prognostic capabilities of invasive exercise testing in a real-world cohort of suspected heart failure patients in whom non-cardiac causes of dyspnea were excluded. Methods: We retrospectively analyzed the survival of 682 patients who underwent right heart catheterization at rest and during exercise between 2007 and 2017 for dyspnea and expected heart failure. Pulmonary capillary wedge pressure (PCWP) at rest and the PCWP response to exercise, expressed as the ratio of PCWP at peak exercise to workload normalized to body weight (PCWL (mmHg/W/kg)), were determined. Mortality data were retrieved from the official German death registry. Results: Over a median follow-up period of 8.5 years, PCWL is a stronger predictor of all-cause mortality than PCWP. Patients featuring a reduced left ventricular ejection fraction (LVEF; p = 0.719). Irrespective of LVEF, an increased PCWL during exercise was associated with a significantly increased mortality (HR 1.950 with preserved LVEF, 95% CI 1.12–3.34, p = 0.018; and HR 3.212 with impaired LVEF, 95% CI 1.75–5.70, p < 0.001). Conclusions: In patients with clinical heart failure, invasive exercise testing improves the prediction of mortality. Subjects with a favorable response to exercise have a relatively low mortality irrespective of left ventricular systolic function.
- Open Access
- 8 August 2022
- Published by Georg Thieme Verlag KG in International Journal of Sports Medicine
- Vol. 43 (13) , 1106-1112
Clarifying the Link Between the Blood Lactate Concentration and Cardiovascular Risk
The blood lactate value at rest (Lacrest) is linked to cardiovascular outcomes. It is unclear whether this association holds true in younger, healthy subjects, especially as the pathophysiological connection between Lacrest and cardiometabolic disease is not well understood. The aim of this study is clarifying the link between Lacrest and cardiovascular risk, and to study explanatory factors for the variance of Lacrest concerning metabolism and physical activity in a population of healthy patient-athletes. The distribution and intra-individual variability of Lacrest was assessed based on 9051 samples. The 10-year cardiovascular risk was then approximated using the Framingham risk score in a group of 1315 samples from patient-athletes. Cross-validated linear regression was used to analyze explanatory variables for Lacrest and 10-year cardiovascular risk. Lacrest is weakly associated with the Framingham score. This association disappears when adjusting for blood lipids. Lacrest is also linked to the predominant type of exercise with endurance athletes featuring a higher Lacrest. Lacrest does not independently predict the estimated cardiovascular risk but is associated with lipid parameters. Moreover, the intra-individual variability of Lacrest is high in a relevant number of subjects, which does not point towards the feasibility to use Lacrest as an individual risk factor. Received: 08 February 2022 Accepted: 28 March 2022 Accepted Manuscript online: 30 March 2022 Article published online: 08 August 2022 © 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 8 August 2022
- Published by Georg Thieme Verlag KG in International Journal of Sports Medicine
- Vol. 43 (13) , 1106-1112
Open AccessClarifying the Link Between the Blood Lactate Concentration and Cardiovascular Risk
The blood lactate value at rest (Lacrest) is linked to cardiovascular outcomes. It is unclear whether this association holds true in younger, healthy subjects, especially as the pathophysiological connection between Lacrest and cardiometabolic disease is not well understood. The aim of this study is clarifying the link between Lacrest and cardiovascular risk, and to study explanatory factors for the variance of Lacrest concerning metabolism and physical activity in a population of healthy patient-athletes. The distribution and intra-individual variability of Lacrest was assessed based on 9051 samples. The 10-year cardiovascular risk was then approximated using the Framingham risk score in a group of 1315 samples from patient-athletes. Cross-validated linear regression was used to analyze explanatory variables for Lacrest and 10-year cardiovascular risk. Lacrest is weakly associated with the Framingham score. This association disappears when adjusting for blood lipids. Lacrest is also linked to the predominant type of exercise with endurance athletes featuring a higher Lacrest. Lacrest does not independently predict the estimated cardiovascular risk but is associated with lipid parameters. Moreover, the intra-individual variability of Lacrest is high in a relevant number of subjects, which does not point towards the feasibility to use Lacrest as an individual risk factor. Received: 08 February 2022 Accepted: 28 March 2022 Accepted Manuscript online: 30 March 2022 Article published online: 08 August 2022 © 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 3 August 2022
- Published by Wiley in Clinical Cardiology
- Vol. 45 (10) , 1053-1059
Clinically unrecognized plasma volume expansion predicts long‐term all‐cause‐mortality in chronic heart failure
Introduction: Chronic heart failure (CHF) is associated with elevated total blood volume (BV) and distinct phenotypes of total red cell volume (RCV) and plasma volume (PV) elevations. Especially PV expansion during clinical decompensation is linked with adverse clinical outcomes. The role of PV expansion in compensated CHF patients is less clear. Aim of the present study is to investigate the impact of BV parameters on long‐term mortality in CHF patients investigated at a compensated state.Methods and Results: BV, PV and RCV were determined in 44 (9 female) compensated CHF patients using an abbreviated carbon monoxide method, who were followed up for 6.0 years, (range: 3.7–6.5 years) for all‐cause mortality. In univariate analysis PV expansion but not BV and RCV predicted all‐cause mortality (p = .021). A cutoff of 1800 ml PV/m² body‐surface area allows stratification for all‐cause mortality (p = .044). PV expansion but not RCV reduction explains the significantly lower hematocrit values of nonsurvivors.Discussion: In this pilot study, PV expansion, which was unnoticed from a clinician's perspective, but is indicated by significantly lower hematocrit, appears to be a relevant predictor of long‐term all‐cause mortality. Whether PV expansion constitutes an adverse CHF phenotype and can be targeted by diuretic therapy is currently unclear.
- 3 August 2022
- Published by Wiley in Clinical Cardiology
- Vol. 45 (10) , 1053-1059
Open AccessClinically unrecognized plasma volume expansion predicts long‐term all‐cause‐mortality in chronic heart failure
Introduction: Chronic heart failure (CHF) is associated with elevated total blood volume (BV) and distinct phenotypes of total red cell volume (RCV) and plasma volume (PV) elevations. Especially PV expansion during clinical decompensation is linked with adverse clinical outcomes. The role of PV expansion in compensated CHF patients is less clear. Aim of the present study is to investigate the impact of BV parameters on long‐term mortality in CHF patients investigated at a compensated state.Methods and Results: BV, PV and RCV were determined in 44 (9 female) compensated CHF patients using an abbreviated carbon monoxide method, who were followed up for 6.0 years, (range: 3.7–6.5 years) for all‐cause mortality. In univariate analysis PV expansion but not BV and RCV predicted all‐cause mortality (p = .021). A cutoff of 1800 ml PV/m² body‐surface area allows stratification for all‐cause mortality (p = .044). PV expansion but not RCV reduction explains the significantly lower hematocrit values of nonsurvivors.Discussion: In this pilot study, PV expansion, which was unnoticed from a clinician's perspective, but is indicated by significantly lower hematocrit, appears to be a relevant predictor of long‐term all‐cause mortality. Whether PV expansion constitutes an adverse CHF phenotype and can be targeted by diuretic therapy is currently unclear.
- Open Access
- 1 May 2022
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 29 (Supplement)
Invasive exercise hemodynamics predict survival in patients with clinical heart failure irrespective of left ventricular systolic function
Type of funding sources: None. When aiming to stratify heart failure patients for mortality risk, exercise stress testing has proven to be relevant in specific populations of heart failure patients, but is not universally applied. Analysis of left ventricular systolic function (LVEF) remains the cornerstone for stratifying heart failure patients for prognosis and clinical treatment. The aim of the present study is to investigate the prognostic capabilities of invasive exercise testing in a real-world cohort of suspected heart failure patients in whom non-cardiac causes of dyspnea were excluded. We retrospectively analyzed survival of patients who underwent right heart catheterization at rest and during exercise between 2007 to 2017 for dyspnea and expected heart failure. Pulmonary capillary wedge pressure (PCWP) at rest and the PCWP response to exercise, expressed as the ratio of PCWP at peak exercise to workload normalized to body weight [PCWL (mmHg/W/kg)], were determined. Mortality data was deducted from the official German death registry. A total of 682 patients [aged 64.1 ± 12 years, 269 (39.2%) women] were included. Based on LVEF, 515 patients (76.4%) had sustained LVEF ≥50%, 71 patients (10.5%) had heart failure with mildly-impaired LVEF (40-49%) and 88 patients (13.1%) had heart failure with reduced LVEF (≤40%). Absolute LVEF was not associated with all-cause mortality (HR 0.995; 95% CI 0.99-1.00; p=0.231). While increases in PCWP at rest an PCWL during exercise were both associated with death, the discriminative properties of pressure measurements derived during exercise were superior in ROC-analysis (AUC 0.637 for PCWP and AUC 0.728 for PCWL, pDiscussion: In patients with clinical heart failure, invasive exercise testing improves the prediction of mortality. Subjects with a normal response to exercise have a relatively low mortality irrespective of systolic function. A: AUC analysis B: Surival Probablity A: AUC analysis B: Surival Probablity
- 1 May 2022
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 29 (Supplement)
Open AccessInvasive exercise hemodynamics predict survival in patients with clinical heart failure irrespective of left ventricular systolic function
Type of funding sources: None. When aiming to stratify heart failure patients for mortality risk, exercise stress testing has proven to be relevant in specific populations of heart failure patients, but is not universally applied. Analysis of left ventricular systolic function (LVEF) remains the cornerstone for stratifying heart failure patients for prognosis and clinical treatment. The aim of the present study is to investigate the prognostic capabilities of invasive exercise testing in a real-world cohort of suspected heart failure patients in whom non-cardiac causes of dyspnea were excluded. We retrospectively analyzed survival of patients who underwent right heart catheterization at rest and during exercise between 2007 to 2017 for dyspnea and expected heart failure. Pulmonary capillary wedge pressure (PCWP) at rest and the PCWP response to exercise, expressed as the ratio of PCWP at peak exercise to workload normalized to body weight [PCWL (mmHg/W/kg)], were determined. Mortality data was deducted from the official German death registry. A total of 682 patients [aged 64.1 ± 12 years, 269 (39.2%) women] were included. Based on LVEF, 515 patients (76.4%) had sustained LVEF ≥50%, 71 patients (10.5%) had heart failure with mildly-impaired LVEF (40-49%) and 88 patients (13.1%) had heart failure with reduced LVEF (≤40%). Absolute LVEF was not associated with all-cause mortality (HR 0.995; 95% CI 0.99-1.00; p=0.231). While increases in PCWP at rest an PCWL during exercise were both associated with death, the discriminative properties of pressure measurements derived during exercise were superior in ROC-analysis (AUC 0.637 for PCWP and AUC 0.728 for PCWL, pDiscussion: In patients with clinical heart failure, invasive exercise testing improves the prediction of mortality. Subjects with a normal response to exercise have a relatively low mortality irrespective of systolic function. A: AUC analysis B: Surival Probablity A: AUC analysis B: Surival Probablity
- Open Access
- 28 February 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (5) , 1332
Echocardiographic and Electrocardiographic Determinants of Atrial Cardiomyopathy Identify Patients with Atrial Fibrillation at Risk for Left Atrial Thrombogenesis
Objective: Atrial cardiomyopathy (ACM) is associated with development of AF, left atrial (LA) thrombogenesis, and stroke. Diagnosis of ACM is feasible using both echocardiographic LA strain imaging and measurement of the amplified p-wave duration (APWD) in digital 12-lead-ECG. We sought to determine the thresholds of LA global longitudinal strain (LA-GLS) and APWD that identify patients with AF at risk for LA appendage (LAA) thrombogenesis. Methods: One hundred and twenty-eight patients with a history of AF were included. Left atrial appendage maximal flow velocity (LAA-Vel, in TEE), LA-GLS (TTE), and APWD (digital 12-lead-ECG) were measured in all patients. ROC analysis was performed for each method to determine the thresholds for LA-GLS and the APWD, enabling diagnosis of patients with LAA-thrombus. Results: Significant differences in LA-GLS were found during both rhythms (SR and AF) between the thrombus group and control group: LA-GLS in SR: 14.3 ± 7.4% vs. 24.6 ± 9.0%, p < 0.001 and in AF: 11.4 ± 4.2% vs. 16.1 ± 5.0%, p = 0.045. ROC analysis revealed a threshold of 17.45% for the entire cohort (AUC 0.82, sensitivity: 84.6%, specificity: 63.6%, Negative Predictive Value (NPV): 94.3%) with additional rhythm-specific thresholds: 19.1% in SR and 13.9% in AF, and a threshold of 165 ms for APWD (AUC 0.90, sensitivity: 88.5%, specificity: 75.5%, NPV: 96.2%) as optimal discriminators of LAA-thrombus. Moreover, both LA-GLS and APWD correlated well with the established contractile LA-parameter LAA-Vel in TEE (r = 0.39, p < 0.001 and r = −0.39, p < 0.001, respectively). Conclusion: LA-GLS and APWD are valuable diagnostic predictors of left atrial thrombogenesis in patients with AF.
- 28 February 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (5) , 1332
Open AccessEchocardiographic and Electrocardiographic Determinants of Atrial Cardiomyopathy Identify Patients with Atrial Fibrillation at Risk for Left Atrial Thrombogenesis
Objective: Atrial cardiomyopathy (ACM) is associated with development of AF, left atrial (LA) thrombogenesis, and stroke. Diagnosis of ACM is feasible using both echocardiographic LA strain imaging and measurement of the amplified p-wave duration (APWD) in digital 12-lead-ECG. We sought to determine the thresholds of LA global longitudinal strain (LA-GLS) and APWD that identify patients with AF at risk for LA appendage (LAA) thrombogenesis. Methods: One hundred and twenty-eight patients with a history of AF were included. Left atrial appendage maximal flow velocity (LAA-Vel, in TEE), LA-GLS (TTE), and APWD (digital 12-lead-ECG) were measured in all patients. ROC analysis was performed for each method to determine the thresholds for LA-GLS and the APWD, enabling diagnosis of patients with LAA-thrombus. Results: Significant differences in LA-GLS were found during both rhythms (SR and AF) between the thrombus group and control group: LA-GLS in SR: 14.3 ± 7.4% vs. 24.6 ± 9.0%, p < 0.001 and in AF: 11.4 ± 4.2% vs. 16.1 ± 5.0%, p = 0.045. ROC analysis revealed a threshold of 17.45% for the entire cohort (AUC 0.82, sensitivity: 84.6%, specificity: 63.6%, Negative Predictive Value (NPV): 94.3%) with additional rhythm-specific thresholds: 19.1% in SR and 13.9% in AF, and a threshold of 165 ms for APWD (AUC 0.90, sensitivity: 88.5%, specificity: 75.5%, NPV: 96.2%) as optimal discriminators of LAA-thrombus. Moreover, both LA-GLS and APWD correlated well with the established contractile LA-parameter LAA-Vel in TEE (r = 0.39, p < 0.001 and r = −0.39, p < 0.001, respectively). Conclusion: LA-GLS and APWD are valuable diagnostic predictors of left atrial thrombogenesis in patients with AF.
- Open Access
- 20 December 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-6
Estimated plasma volume status is a modest predictor of true plasma volume excess in compensated chronic heart failure patients
Plasma volume and especially plasma volume excess is a relevant predictor for the clinical outcome of heart failure patients. In recent years, estimated plasma volume based on anthropometric characteristics and blood parameters has been used whilst direct measurement of plasma volume has not entered clinical routine. It is unclear whether the estimation of plasma volume can predict a true plasma volume excess. Plasma volume was measured in 47 heart failure patients (CHF, 10 female) using an abbreviated carbon monoxide rebreathing method. Plasma volume and plasma volume status were also estimated based on two prediction formulas (Hakim, Kaplan). The predictive properties of the estimated plasma volume status to detect true plasma volume excess > 10% were analysed based on logistic regression and receiver operator characteristics. The area under the curve (AUC) to detect plasma volume excess based on calculation of plasma volume by the Hakim formula is 0.65 (with a positive predictive value (PPV) of 0.62 at a threshold of − 16.5%) whilst the AUC for the Kaplan formula is 0.72 (PPV = 0.67 at a threshold of − 6.3%). Only the estimated plasma volume status based on prediction of plasma volume by the Kaplan formula formally appears as an acceptable predictor of true plasma volume excess, whereas calculation based on the Hakim formula does not sufficiently predict a true plasma volume excess. The low positive predictive values for both methods suggest that plasma volume status estimation based on these formulas is not suitable for clinical decision making.
- 20 December 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-6
Open AccessEstimated plasma volume status is a modest predictor of true plasma volume excess in compensated chronic heart failure patients
Plasma volume and especially plasma volume excess is a relevant predictor for the clinical outcome of heart failure patients. In recent years, estimated plasma volume based on anthropometric characteristics and blood parameters has been used whilst direct measurement of plasma volume has not entered clinical routine. It is unclear whether the estimation of plasma volume can predict a true plasma volume excess. Plasma volume was measured in 47 heart failure patients (CHF, 10 female) using an abbreviated carbon monoxide rebreathing method. Plasma volume and plasma volume status were also estimated based on two prediction formulas (Hakim, Kaplan). The predictive properties of the estimated plasma volume status to detect true plasma volume excess > 10% were analysed based on logistic regression and receiver operator characteristics. The area under the curve (AUC) to detect plasma volume excess based on calculation of plasma volume by the Hakim formula is 0.65 (with a positive predictive value (PPV) of 0.62 at a threshold of − 16.5%) whilst the AUC for the Kaplan formula is 0.72 (PPV = 0.67 at a threshold of − 6.3%). Only the estimated plasma volume status based on prediction of plasma volume by the Kaplan formula formally appears as an acceptable predictor of true plasma volume excess, whereas calculation based on the Hakim formula does not sufficiently predict a true plasma volume excess. The low positive predictive values for both methods suggest that plasma volume status estimation based on these formulas is not suitable for clinical decision making.
- Open Access
- 5 January 2021
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 8 (2) , 1696-1699
Time Course of Red Cell Volume and Plasma Volume Over Six Months in Compensated Chronic Heart Failure
Background: In patients with chronic heart failure (CHF), volume overload is usually described as an expansion of plasma volume (PV). Additional red cell volume (RCV) expansion also occurs in a relevant fraction of compensated CHF patients. So far, little is known about the stability of these vascular volumes and possible volume excess in compensated CHF patients over time. Methods and results: This study aims at quantification of blood volume and its components, RCV and PV (raw values and adjusted for sex and anthropometric characteristics, expressed as per cent of the expected normal value), using an abbreviated carbon monoxide (CO) rebreathing method (aCORM) in 14 patients (two women) with systolic CHF at baseline and at a follow-up visit after approximately 6 months. While a vast heterogeneity was observed concerning RCV (82% to 134% of normalized alues) and PV (72% to 131% of normalized values), the vascular volumes showed a mean change of 1.2% and −1.3% after a mean follow-up of 183 days. Conclusions: The vascular volumes including individual volume excess appear to be stable in compensated CHF patients. The reason for this individual volume response concerning both RCV and PV in CHF remains unclear and deserves further clarification.
- 5 January 2021
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 8 (2) , 1696-1699
Open AccessTime Course of Red Cell Volume and Plasma Volume Over Six Months in Compensated Chronic Heart Failure
Background: In patients with chronic heart failure (CHF), volume overload is usually described as an expansion of plasma volume (PV). Additional red cell volume (RCV) expansion also occurs in a relevant fraction of compensated CHF patients. So far, little is known about the stability of these vascular volumes and possible volume excess in compensated CHF patients over time. Methods and results: This study aims at quantification of blood volume and its components, RCV and PV (raw values and adjusted for sex and anthropometric characteristics, expressed as per cent of the expected normal value), using an abbreviated carbon monoxide (CO) rebreathing method (aCORM) in 14 patients (two women) with systolic CHF at baseline and at a follow-up visit after approximately 6 months. While a vast heterogeneity was observed concerning RCV (82% to 134% of normalized alues) and PV (72% to 131% of normalized values), the vascular volumes showed a mean change of 1.2% and −1.3% after a mean follow-up of 183 days. Conclusions: The vascular volumes including individual volume excess appear to be stable in compensated CHF patients. The reason for this individual volume response concerning both RCV and PV in CHF remains unclear and deserves further clarification.
- Open Access
- 1 June 2020
- Published by Wiley in Physiological Reports
- Vol. 8 (11) , e14468
Letter to the editor: "Comment on: Application of the optimized carbon monoxide rebreathing method for the measurement of total haemoglobin mass in chronic liver disease"
- 1 June 2020
- Published by Wiley in Physiological Reports
- Vol. 8 (11) , e14468
Open AccessLetter to the editor: "Comment on: Application of the optimized carbon monoxide rebreathing method for the measurement of total haemoglobin mass in chronic liver disease"
- 1 May 2020
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 26 (5) , 420-428
Increased Red Cell Volume Is a Relevant Contributing Factor to an Expanded Blood Volume in Compensated Systolic Chronic Heart Failure
- 1 May 2020
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 26 (5) , 420-428
Increased Red Cell Volume Is a Relevant Contributing Factor to an Expanded Blood Volume in Compensated Systolic Chronic Heart Failure